Immunocore Holdings Plc ( (IMCR) ) has released its Q2 earnings. Here is a breakdown of the information Immunocore Holdings Plc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immunocore Holdings Plc is a biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, utilizing its proprietary ImmTAX platform. In its latest earnings report for the quarter ended June 30, 2025, Immunocore Holdings Plc reported a total revenue of $97.96 million, a significant increase from $75.4 million in the same period last year, primarily driven by the sales of its lead product, KIMMTRAK, which is now approved in 39 countries. The company experienced a net loss of $10.3 million for the quarter, an improvement from the $11.6 million loss in the previous year, as it continues to invest in research and development, with expenses totaling $69 million. Immunocore’s financial position remains strong with cash and cash equivalents of $487.9 million, supported by successful commercialization efforts and strategic investments in its pipeline. Looking ahead, Immunocore Holdings Plc remains committed to expanding the reach of KIMMTRAK and advancing its pipeline, with a focus on maintaining regulatory approvals and exploring new therapeutic areas.